ImmunoBrain Checkpoint (IBC) is a biopharmaceutical company focused on developing a pipeline of disease-modifying immunotherapies for neurological disorders by targeting immune checkpoint pathways. IBCs novel approach to the treatment of neurodegeneration is based on years of innovative scientific discoveries made by Prof. Michal Schwartz of the Weizmann Institute of Science. IBCs lead programs are being developed for the treatment of Alzheimers disease, employing a novel approach of blocking the PD-1/PD-L1 immune checkpoint pathway. In June 2017, Lundbeck, a global pharmaceutical company specializing in therapies for neurological disorders, obtained the rights to IBCs research into treatment for Alzheimers disease. As part of the agreement, Lundbeck will provide the funding for, as well as participate in, additional research that will allow the identification of potential therapies for clinical trials. Lundbeck also obtained minority ownership of IBC and has the exclusive option to take over the rights and activities relating to this technology at a later date.